<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37581843</PMID><DateCompleted><Year>2023</Year><Month>11</Month><Day>15</Day></DateCompleted><DateRevised><Year>2024</Year><Month>01</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1538-2443</ISSN><JournalIssue CitedMedium="Internet"><Volume>29</Volume><Issue>5</Issue><PubDate><Year>2023</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Journal of neurovirology</Title><ISOAbbreviation>J Neurovirol</ISOAbbreviation></Journal><ArticleTitle>Evolving etiologies, comorbidities, survival, and costs of care in adult encephalitis.</ArticleTitle><Pagination><StartPage>605</StartPage><EndPage>613</EndPage><MedlinePgn>605-613</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s13365-023-01165-9</ELocationID><Abstract><AbstractText>Encephalitis is a central nervous system disorder, often caused by infectious agents or aberrant immune responses. We investigated causes, comorbidities, costs, and outcomes of encephalitis in a population-based cohort. ICD-10 codes corresponding to encephalitis were used to identify health services records for all adults from 2004 to 2019. Data were cross-validated for identified diagnoses based on laboratory confirmation using univariate and multivariate statistical analyses. We identified persons with a diagnosis of encephalitis and abnormal cerebrospinal fluid (CSF) results (n = 581) in whom viral genome was detected (n = 315) in a population of 3.2 million adults from 2004 to 2019. Viral genome-positive CSF samples included HSV-1 (n = 133), VZV (n = 116), HSV-2 (n = 34), enterovirus (n = 4), EBV (n = 5), and CMV (n = 3) with the remaining viruses included JCV (n = 12) and HHV-6 (n = 1). The mean Charlson Comorbidity Index (2.0) and mortality rate (37.6%) were significantly higher in the CSF viral genome-negative encephalitis group although the mean costs of care were significantly higher for the CSF viral genome-positive group. Cumulative incidence rates showed increased CSF VZV detection in persons with encephalitis, which predominated in persons over 65 years with a higher mean Charlson index. We detected HSV-2 and VZV more frequently in CSF from encephalitis cases with greater material-social deprivation. The mean costs of care were significantly greater for HSV-1 encephalitis group. Encephalitis remains an important cause of neurological disability and death with a viral etiology in 54.2% of affected adults accompanied by substantial costs of care and mortality. Virus-associated encephalitis is evolving with increased VZV detection, especially in older persons.</AbstractText><CopyrightInformation>© 2023. The Author(s) under exclusive licence to The Journal of NeuroVirology, Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bakal</LastName><ForeName>J A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Provincial Research Data Services-Alberta Health Services, Edmonton, AB, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Community Health Sciences, University of Calgary, Calgary, AB, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rivera</LastName><ForeName>R</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>School of Public Health, University of Alberta, Edmonton, AB, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Charlton</LastName><ForeName>C</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Public Health Laboratory, Alberta Precision Laboratories, Edmonton, AB, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, AB, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Li Ka Shing Institute of Virology, Edmonton, AB, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Plitt</LastName><ForeName>S</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Public Health Laboratory, Alberta Precision Laboratories, Edmonton, AB, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Power</LastName><ForeName>C</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-5131-9711</Identifier><AffiliationInfo><Affiliation>Division of Neurology, Department of Medicine, Medical Research Centre, University of Alberta, 6-11 Heritage, Edmonton, AB, Canada. chris.power@ualberta.ca.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Microbiology, Immunology &amp; Infectious Diseases, University of Calgary, Calgary, AB, Canada. chris.power@ualberta.ca.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>08</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurovirol</MedlineTA><NlmUniqueID>9508123</NlmUniqueID><ISSNLinking>1355-0284</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004279">DNA, Viral</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014780" MajorTopicYN="Y">Viruses</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018259" MajorTopicYN="Y">Herpesvirus 1, Human</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018792" MajorTopicYN="Y">Encephalitis, Viral</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018258" MajorTopicYN="N">Herpesvirus 2, Human</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004279" MajorTopicYN="N">DNA, Viral</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014645" MajorTopicYN="N">Herpesvirus 3, Human</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Cerebrospinal fluid</Keyword><Keyword MajorTopicYN="N">Comorbidity</Keyword><Keyword MajorTopicYN="N">Cost of care</Keyword><Keyword MajorTopicYN="N">Encephalitis</Keyword><Keyword MajorTopicYN="N">PCR</Keyword><Keyword MajorTopicYN="N">Population epidemiology</Keyword><Keyword MajorTopicYN="N">Survival</Keyword><Keyword MajorTopicYN="N">Virus</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>3</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>7</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>7</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>11</Month><Day>15</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>8</Month><Day>15</Day><Hour>12</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>8</Month><Day>15</Day><Hour>11</Hour><Minute>10</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37581843</ArticleId><ArticleId IdType="doi">10.1007/s13365-023-01165-9</ArticleId><ArticleId IdType="pii">10.1007/s13365-023-01165-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Armangue T, Spatola M, Vlagea A, Mattozzi S, Carceles-Cordon M, Martinez-Heras E et al (2018) Frequency, symptoms, risk factors, and outcomes of autoimmune encephalitis after herpes simplex encephalitis: a prospective observational study and retrospective analysis. Lancet Neurol 17(9):760–772</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(18)30244-8</ArticleId><ArticleId IdType="pubmed">30049614</ArticleId><ArticleId IdType="pmc">6128696</ArticleId></ArticleIdList></Reference><Reference><Citation>Balcom EF, Doan MAL, Branton WG, Jovel J, Blevins G, Edguer B et al (2018) Human pegivirus-1 associated leukoencephalitis: clinical and molecular features. Ann Neurol 84(5):781–787</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.25343</ArticleId><ArticleId IdType="pubmed">30246885</ArticleId></ArticleIdList></Reference><Reference><Citation>Bakal JA, Charlton CL, Hlavay B, Jansen GH, Svenson LW, Power C (2021) Progressive multifocal leukoencephalopathy and Creutzfeldt-Jakob disease: population-wide incidences, comorbidities, costs of care, and outcomes. J Neurovirol 27(3):476–481</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13365-021-00983-z</ArticleId><ArticleId IdType="pubmed">33978904</ArticleId></ArticleIdList></Reference><Reference><Citation>Bumburidi Y, Utepbergenova G, Yerezhepov B, Berdiyarova N, Kulzhanova K, Head J et al (2021) Etiology of acute meningitis and encephalitis from hospital-based surveillance in South Kazakhstan oblast, February 2017-January 2018. PLoS ONE 16(5):e0251494</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0251494</ArticleId><ArticleId IdType="pubmed">33989305</ArticleId><ArticleId IdType="pmc">8121361</ArticleId></ArticleIdList></Reference><Reference><Citation>Bystritsky RJ, Chow FC (2022) Infectious meningitis and encephalitis. Neurol Clin 40(1):77–91</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ncl.2021.08.006</ArticleId><ArticleId IdType="pubmed">34798976</ArticleId></ArticleIdList></Reference><Reference><Citation>Dalmau J, Graus F (2018) Antibody-Mediated Encephalitis. N Engl J Med 378(9):840–851</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra1708712</ArticleId><ArticleId IdType="pubmed">29490181</ArticleId></ArticleIdList></Reference><Reference><Citation>Dittrich T, Marsch S, Egli A, Ruegg S, De Marchis GM, Tschudin-Sutter S et al (2020) Predictors of infectious meningitis or encephalitis: the yield of cerebrospinal fluid in a cross-sectional study. BMC Infect Dis 20(1):304</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-020-05022-6</ArticleId><ArticleId IdType="pubmed">32326881</ArticleId><ArticleId IdType="pmc">7181581</ArticleId></ArticleIdList></Reference><Reference><Citation>Dubey D, Pittock SJ, Kelly CR, McKeon A, Lopez-Chiriboga AS, Lennon VA et al (2018) Autoimmune encephalitis epidemiology and a comparison to infectious encephalitis. Ann Neurol 83(1):166–177</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.25131</ArticleId><ArticleId IdType="pubmed">29293273</ArticleId><ArticleId IdType="pmc">6011827</ArticleId></ArticleIdList></Reference><Reference><Citation>Ellul M, Solomon T (2018) Acute encephalitis - diagnosis and management. Clin Med (lond) 18(2):155–159</Citation><ArticleIdList><ArticleId IdType="doi">10.7861/clinmedicine.18-2-155</ArticleId><ArticleId IdType="pubmed">29626021</ArticleId></ArticleIdList></Reference><Reference><Citation>Fanaroff AC, Cyr D, Neely ML, Bakal J, White HD, Fox KAA et al (2018) Days alive and out of hospital: exploring a patient-centered, pragmatic outcome in a clinical trial of patients with acute coronary syndromes. Circ Cardiovasc Qual Outcomes 11(12):e004755</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCOUTCOMES.118.004755</ArticleId><ArticleId IdType="pubmed">30562068</ArticleId><ArticleId IdType="pmc">6347414</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilden DH, Kleinschmidt-DeMasters BK, LaGuardia JJ, Mahalingam R, Cohrs RJ (2000) Neurologic complications of the reactivation of varicella-zoster virus. N Engl J Med 342(9):635–645</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM200003023420906</ArticleId><ArticleId IdType="pubmed">10699164</ArticleId></ArticleIdList></Reference><Reference><Citation>Glaser CA, Gilliam S, Schnurr D, Forghani B, Honarmand S, Khetsuriani N et al (2003) In search of encephalitis etiologies: diagnostic challenges in the California Encephalitis Project, 1998–2000. Clin Infect Dis 36(6):731–742</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/367841</ArticleId><ArticleId IdType="pubmed">12627357</ArticleId></ArticleIdList></Reference><Reference><Citation>Halperin JJ (2017) Diagnosis and management of acute encephalitis. Handb Clin Neurol 140:337–347</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/B978-0-444-63600-3.00018-0</ArticleId><ArticleId IdType="pubmed">28187808</ArticleId></ArticleIdList></Reference><Reference><Citation>Iro MA, Sadarangani M, Goldacre R, Nickless A, Pollard AJ, Goldacre MJ (2017) 30-year trends in admission rates for encephalitis in children in England and effect of improved diagnostics and measles-mumps-rubella vaccination: a population-based observational study. Lancet Infect Dis 17(4):422–430</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(17)30114-7</ArticleId><ArticleId IdType="pubmed">28259562</ArticleId></ArticleIdList></Reference><Reference><Citation>Jmor F, Emsley HC, Fischer M, Solomon T, Lewthwaite P (2008) The incidence of acute encephalitis syndrome in Western industrialised and tropical countries. Virol J 5:134</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1743-422X-5-134</ArticleId><ArticleId IdType="pubmed">18973679</ArticleId><ArticleId IdType="pmc">2583971</ArticleId></ArticleIdList></Reference><Reference><Citation>Kennedy PGE, Quan PL, Lipkin WI (2017) Viral encephalitis of unknown cause: current perspective and recent advances. Viruses 9(6)</Citation></Reference><Reference><Citation>Kiyani M, Liu B, Charalambous LT, Adil SM, Hodges SE, Yang S et al (2020) The longitudinal health economic impact of viral encephalitis in the United States. J Med Microbiol 69(2):270–279</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/jmm.0.001153</ArticleId><ArticleId IdType="pubmed">32040394</ArticleId><ArticleId IdType="pmc">7431099</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee GH, Kim J, Kim HW, Cho JW (2021) Herpes simplex viruses (1 and 2) and varicella-zoster virus infections in an adult population with aseptic meningitis or encephalitis: a nine-year retrospective clinical study. Medicine (baltimore) 100(46):e27856</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MD.0000000000027856</ArticleId><ArticleId IdType="pubmed">34797322</ArticleId></ArticleIdList></Reference><Reference><Citation>McDonald E, Mathis S, Martin SW, Erin Staples J, Fischer M, Lindsey NP (2021) Surveillance for West Nile virus disease - United States, 2009–2018. Am J Transplant 21(5):1959–1974</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ajt.16595</ArticleId><ArticleId IdType="pubmed">33939278</ArticleId></ArticleIdList></Reference><Reference><Citation>Michael BD, Griffiths MJ, Granerod J, Brown D, Keir G, Wnek M et al (2016) The interleukin-1 balance during encephalitis is associated with clinical severity, blood-brain barrier permeability, neuroimaging changes, and disease outcome. J Infect Dis 213(10):1651–1660</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiv771</ArticleId><ArticleId IdType="pubmed">26712949</ArticleId></ArticleIdList></Reference><Reference><Citation>Pampalon R, Hamel D, Gamache P, Raymond G (2009) A deprivation index for health planning in Canada. Chronic Dis Can 29(4):178–191</Citation><ArticleIdList><ArticleId IdType="doi">10.24095/hpcdp.29.4.05</ArticleId><ArticleId IdType="pubmed">19804682</ArticleId></ArticleIdList></Reference><Reference><Citation>Parpia AS, Li Y, Chen C, Dhar B, Crowcroft NS (2016) Encephalitis, Ontario, Canada, 2002–2013. Emerg Infect Dis 22(3):426–432</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid2203.151545</ArticleId><ArticleId IdType="pubmed">26890626</ArticleId><ArticleId IdType="pmc">4766895</ArticleId></ArticleIdList></Reference><Reference><Citation>Quan H, Li B, Couris CM, Fushimi K, Graham P, Hider P et al (2011) Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol 173(6):676–682</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/aje/kwq433</ArticleId><ArticleId IdType="pubmed">21330339</ArticleId></ArticleIdList></Reference><Reference><Citation>Sarnecki L, Gordon L (2009) Analysis of acuity trends using resource intensity weights via the CIHI Portal. Stud Health Technol Inform 143:42–46</Citation><ArticleIdList><ArticleId IdType="pubmed">19380913</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh TD, Fugate JE, Rabinstein AA (2015) The spectrum of acute encephalitis: causes, management, and predictors of outcome. Neurology 84(4):359–366</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000001190</ArticleId><ArticleId IdType="pubmed">25540320</ArticleId></ArticleIdList></Reference><Reference><Citation>Snyder RE, Cooksey GS, Kramer V, Jain S, Vugia DJ (2021) West Nile virus-associated hospitalizations, California, 2004–2017. Clin Infect Dis 73(3):441–447</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciaa749</ArticleId><ArticleId IdType="pubmed">32525967</ArticleId></ArticleIdList></Reference><Reference><Citation>Swanson PA 2nd, McGavern DB (2015) Viral diseases of the central nervous system. Curr Opin Virol 11:44–54</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.coviro.2014.12.009</ArticleId><ArticleId IdType="pubmed">25681709</ArticleId><ArticleId IdType="pmc">4456224</ArticleId></ArticleIdList></Reference><Reference><Citation>Tam J, Tran D, Bettinger JA, Moore D, Sauve L, Jadavji T et al (2020) Review of pediatric encephalitis and encephalopathy cases following immunization reported to the Canadian Immunization Monitoring Program Active (IMPACT) from 1992 to 2012. Vaccine 38(28):4457–4463</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2020.04.035</ArticleId><ArticleId IdType="pubmed">32414652</ArticleId></ArticleIdList></Reference><Reference><Citation>Therneau T, Atkinson B (2018) Rpart: recursive partitioning and regression trees. R Package Version 41–13</Citation></Reference><Reference><Citation>Tyler KL (2018) Acute Viral Encephalitis. N Engl J Med 379(6):557–566</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra1708714</ArticleId><ArticleId IdType="pubmed">30089069</ArticleId></ArticleIdList></Reference><Reference><Citation>Venkatesan A, Tunkel AR, Bloch KC, Lauring AS, Sejvar J, Bitnun A et al (2013) Case definitions, diagnostic algorithms, and priorities in encephalitis: consensus statement of the international encephalitis consortium. Clin Infect Dis 57(8):1114–1128</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/cit458</ArticleId><ArticleId IdType="pubmed">23861361</ArticleId><ArticleId IdType="pmc">3783060</ArticleId></ArticleIdList></Reference><Reference><Citation>Wiese AD, Griffin MR, Stein CM, Schaffner W, Greevy RA, Mitchel EF Jr et al (2018) Validation of discharge diagnosis codes to identify serious infections among middle age and older adults. BMJ Open 8(6):e020857</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2017-020857</ArticleId><ArticleId IdType="pubmed">29921683</ArticleId><ArticleId IdType="pmc">6009457</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu B, Crew B, Maxwell T (2021) Measuring the burden. Nature 598:S18–S19</Citation></Reference><Reference><Citation>Zou J, Krentz HB, Lang R, Beckthold B, Fonseca K, Gill MJ (2022) Seropositivity, risks, and morbidity from varicella-zoster virus infections in an adult PWH cohort from 2000–2020. Open Forum Infect Dis 9(8):ofac395</Citation></Reference></ReferenceList></PubmedData></PubmedArticle>